James Neal - 14 Nov 2024 Form 3 Insider Report for Akari Therapeutics Plc (AKTX)

Role
Director
Signature
/s/ Wendy F. DiCicco, as Attorney-in-Fact
Issuer symbol
AKTX
Transactions as of
14 Nov 2024
Transactions value $
$0
Form type
3
Filing time
22 Nov 2024, 16:30:16 UTC
Previous filing
18 Sep 2024
Next filing
26 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AKTX Ordinary Shares, par value $0.0001 per share 22.2M 14 Nov 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AKTX Warrants (Right to Buy) 14 Nov 2024 Ordinary Shares, par value $0.0001 per share 19.6M $0.00 Direct F1
holding AKTX Stock Option (Right to Buy) 14 Nov 2024 Ordinary Shares, par value $0.0001 per share 294M $0.00 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares.
F2 Subject to the Reporting Person's continued service with the Issuer and there being an effective Form S-8 Registration Statement (a "Form S-8") on file with the SEC covering the issuance of the Ordinary Shares underlying such option, this option shall vest with respect to one third of the underlying shares on each of (i) the effective date of the Form S-8, (ii) December 31, 2024 and (iii) December 31, 2025.

Remarks:

Exhibit 24 - Power of Attorney